Showing 2901-2910 of 5685 results for "".
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- Open-Angle Glaucoma in One Eye Likely to Develop in the Otherhttps://modernod.com/news/open-angle-glaucoma-in-one-eye-likely-to-develop-in-the-other/2479915/Patients with open-angle glaucoma in one eye are at increased risk for developing glaucoma in the second eye, researchers report, according to Reuters Health. “Among patients with newly diagnosed open-angle glaucoma, almost ha
- MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2479927/MeiraGTx Holdings announced that the FDA has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGB3 gene. ACHM is an inherited retinal disease that severely limits a person’s sight
- Web Vision Technologies Receives Grants to Develop Vision Testing Devices for NASAhttps://modernod.com/news/web-vision-technologies-receives-grants-to-develop-vision-testing-devices-for-nasa/2479953/Web Vision Technologies was recently awarded two grants from Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine to develop vision-testing devices for the National Aeronautical Space Administration (NASA) to be used on the International Space Station (ISS). The
- Trabeculectomy Outcomes Different for Individuals of African vs European Descenthttps://modernod.com/news/trabeculectomy-outcomes-different-for-patients-of-african-vs-european-descent/2479955/Individuals of African descent (AD) and those of European descent (ED) tend to have different outcomes after trabeculectomy with mitomycin C, according to a report in JAMA Ophthalmology. “African descent was associate
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- Wills Eye Sponsors First Early Feasibility Study of a New Implantable Device for Blind Retinitis Pigmentosa Patientshttps://modernod.com/news/wills-eye-sponsors-first-us-early-feasibility-study-of-a-new-implantable-device-for-blind-retinitis-pigmentosa-patients/2479960/Wills Eye Hospital has been given FDA approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to retinitis pigmentosa (RP). The Alpha AMS is manufactured by Retina Implant AG, Reutlingen,
- AAO Launches New Scientific Journal Dedicated to Glaucoma Researchhttps://modernod.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/The American Academy of Ophthalmology announced the launch of Ophthalmology Glaucoma, a scientific journal focused exclusively on glaucoma. As development of next-generation glaucoma devices and drugs surges, Ophthalmology Glaucoma offers researchers an expanded opportunity to pu
- Topical Presbyopia Treatment Advances in Clinical Developmenthttps://modernod.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/Presbyopia Therapies announced that the primary efficacy and safety endpoints have been met in a phase 2b study of its PRX ophthalmic solution. PRX demonstrated a 3 line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improve
- OCT Angiography Predicts Exudation in Macular Degenerationhttps://modernod.com/news/oct-angiography-predicts-exudation-in-macular-degeneration/2479981/Optical coherence tomography (OCT) angiography can help predict which eyes affected by age-related macular degeneration are most likely to develop exudation, research shows, according to a report in Medscape. The new technology can